Cennerv Pharmaceuticals was established in 2015 by Chakra Biotech Pte Ltd (Chakra), a Singapore-based biotech company set-up in 2001 to address critical unmet needs in the CNS therapeutic space. The premise of Chakra’s drug discovery efforts was on phenotypic screening in relevant animal models of disease. This approach mitigated the risk of insufficient efficacy of the compounds being developed for a particular therapeutic indication. Today, Cennerv Pharmaceuticals works through its subsidiary Cennerv Pharma (S) Pte Ltd (Singapore).